SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma reports 8% fall in Q3 net profit

05 Feb 2015 Evaluate

Aurobindo Pharma has reported results for third quarter ended December 31, 2014.

The company has registered a fall of 5.71% in its net profit at Rs 394.27 crore for the quarter under review as compared to Rs 418.16 crore for the same quarter in the previous year. However, total income of the company has increased 10.39% at Rs 2109.70 crore for Q3FY15 as compared Rs 1911.08 crore for the corresponding quarter previous year.

On the consolidated basis the company’s net profit declined 7.93% to Rs 384.35 crore for the Q3 FY15 as compared to Rs 417.49 crore in Q3 FY14. However, the total income increased by 49.34% to Rs 3202.08 crore in the quarter under review as compared to Rs 2144.12 crore in the corresponding quarter previous year.

Aurobindo Pharma Share Price

1377.90 -7.75 (-0.56%)
20-Apr-2026 09:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.00
Dr. Reddys Lab 1235.40
Cipla 1235.05
Zydus Lifesciences 941.20
Lupin 2330.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×